| scholarly article | Q13442814 |
| P50 | author | Marisol Soengas | Q42911215 |
| P2093 | author name string | M A Nikiforov | |
| J R Marshall | |||
| D Zhuang | |||
| R C Sears | |||
| S Mannava | |||
| C D Morrison | |||
| J A Wawrzyniak | |||
| E E Fink | |||
| A R Omilian | |||
| J C Miecznikowski | |||
| P2860 | cites work | CIP2A expression is increased in prostate cancer | Q21198842 |
| The ubiquitin-specific protease USP28 is required for MYC stability | Q24308568 | ||
| Identification of c-MYC as a target of the APC pathway | Q24310637 | ||
| The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc | Q24314734 | ||
| Identification of PP2A complexes and pathways involved in cell transformation | Q24316472 | ||
| CIP2A inhibits PP2A in human malignancies | Q24319683 | ||
| Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta | Q24319688 | ||
| Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells | Q24321642 | ||
| Myc pathways provoking cell suicide and cancer | Q28190322 | ||
| Determinants of BRAF mutations in primary melanomas | Q28191720 | ||
| Distinct sets of genetic alterations in melanoma | Q29614965 | ||
| c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover | Q73520938 | ||
| BRAFE600-associated senescence-like cell cycle arrest of human naevi | Q29619550 | ||
| Control of cell proliferation by Myc family genes | Q33548120 | ||
| The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence | Q33588743 | ||
| Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation | Q33591386 | ||
| MYC oncogenes and human neoplastic disease | Q33667340 | ||
| Tumor suppressors and oncogenes in cellular senescence. | Q33930350 | ||
| c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells | Q33962550 | ||
| High frequency of BRAF mutations in nevi | Q34160519 | ||
| The Mad and Myc basic domains are functionally equivalent | Q34171815 | ||
| Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells | Q34803825 | ||
| The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation | Q34835596 | ||
| MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. | Q34983172 | ||
| eIF-4E expression and its role in malignancies and metastases. | Q35750118 | ||
| Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation | Q35928960 | ||
| Selective evolutionary pressure from the tissue microenvironment drives tumor progression | Q36206974 | ||
| The WNT/Beta-catenin pathway in melanoma | Q36251062 | ||
| Involvement of PP2A in viral and cellular transformation | Q36318172 | ||
| Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function | Q36580032 | ||
| The Oscar-worthy role of Myc in apoptosis | Q36582963 | ||
| Oncogene-induced cell senescence--halting on the road to cancer | Q36587198 | ||
| Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis | Q36663762 | ||
| Melanoma biology and new targeted therapy | Q36742015 | ||
| Understanding signaling cascades in melanoma | Q37034487 | ||
| MYC-induced cancer cell energy metabolism and therapeutic opportunities | Q37438881 | ||
| Pathways of oncogene-induced senescence in human melanocytic cells | Q37777015 | ||
| Werner syndrome protein limits MYC-induced cellular senescence | Q39895677 | ||
| C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells | Q39954044 | ||
| Inactivation of hCDC4 can cause chromosomal instability | Q40582502 | ||
| Skp2 regulates Myc protein stability and activity | Q40644685 | ||
| Ras enhances Myc protein stability. | Q40967066 | ||
| Proteins of the Myc network: essential regulators of cell growth and differentiation. | Q41035974 | ||
| c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle | Q42115767 | ||
| IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1. | Q42265040 | ||
| Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation | Q43240765 | ||
| Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. | Q53600237 | ||
| P4510 | describes a project that uses | ImageQuant | Q112270642 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1484-1492 | |
| P577 | publication date | 2011-08-08 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells | |
| P478 | volume | 31 |
| Q58796907 | Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma |
| Q38617799 | All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase |
| Q36443322 | B'-protein phosphatase 2A is a functional binding partner of delta-retroviral integrase |
| Q42500610 | CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes |
| Q35755402 | Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma |
| Q38055308 | Controversial aspects of oncogene-induced senescence |
| Q36495207 | Depletion of deoxyribonucleotide pools is an endogenous source of DNA damage in cells undergoing oncogene-induced senescence |
| Q38904928 | Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options. |
| Q41585228 | Detection of Nucleotide Disbalance in Cells Undergoing Oncogene-Induced Senescence |
| Q26865711 | LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential |
| Q38193043 | MYC degradation |
| Q37984547 | Narrowing the knowledge gaps for melanoma |
| Q38722990 | P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells |
| Q47927484 | Pathways from senescence to melanoma: focus on MITF sumoylation. |
| Q36288343 | Pharmacological targeting of guanosine monophosphate synthase suppresses melanoma cell invasion and tumorigenicity. |
| Q38103646 | Protein phosphatase 2A: a target for anticancer therapy |
| Q30657002 | RAB7 counteracts PI3K-driven macropinocytosis activated at early stages of melanoma development |
| Q30464719 | Regulation of c-Myc Protein Abundance by a Protein Phosphatase 2A-Glycogen Synthase Kinase 3β-Negative Feedback Pathway |
| Q92447468 | STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations |
| Q36072016 | Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress |
| Q42380380 | The Immortal Senescence |
| Q38237693 | Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy? |
Search more.